Primary Objective:~Part A. Determine the safety, maximum tolerated dose and/or recommended phase 2 dose of adoptively transferred autologous tumor-targeted IL12 T cells (attIL12 T cell therapy) in combination with cyclophosphamide in patients with advanced/metastatic soft tissue or bone sarcomas~Part B. Characterize the safety and tolerability and assess preliminary efficacy of attIL12-armed T cells in combination with cyclophosphamide by evaluating the 4-month disease control rate (DCR4 months) in patients with recurrent unresectable osteosarcoma~Secondary Objectives:~--Evaluate the anti-tumor efficacy achieved following adoptive transfer of autologous tumor-targeted IL12 T cells (attIL12 T cell therapy) in combination with cyclophosphamide in patients with advanced/metastatic soft tissue or bone sarcomas~Exploratory Objectives:~Characterize the immune response following adoptive transfer of autologous tumor-targeted IL12 T cells (attIL12 T cell therapy) in paired in pre-treatment and on-treatment tumor specimens and peripheral blood samples~Assess FoxP3/CD33/CD8/IFNg expression in pre-treatment and on-treatment tumor specimens and correlate with clinical benefit/anti-tumor response~Determine changes in cell surface vimentin (CSV)-positive circulating tumor cells (CTCs) in peripheral blood before and after adoptive transfer of autologous tumor-targeted IL12 T cells (attIL12 T cell therapy) and correlate with clinical benefit/anti-tumor response
To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.